Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.4 USD | +0.40% | +2.50% | -13.89% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.89% | 1.19B | |
+41.63% | 54.04B | |
+43.57% | 41.96B | |
-1.31% | 41.92B | |
-7.59% | 28.35B | |
+12.43% | 26.35B | |
-22.18% | 19B | |
+7.83% | 13B | |
+28.85% | 12.28B | |
+24.94% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022